Quadramet
- Quadramet
- Samarium Sm 153 lexidronam
- Lexidronam Sm 153
- Sm-153-EDTMP
- SHR-3644
- Create:2006-07-28
- Modify:2025-01-25
- 153Sm-EDTMP
- Quadramet
- samarate(5-)-153Sm, (((1,2-ethanediylbis((nitrilo-kappa-N)bis(methylene)))tetrakis(phosphonato-kappa-O))(8-))-, pentahydrogen, (oc-6-21)
- samarium (153Sm) lexidronam
- samarium ethylenediaminetetramethylenephosphonate
- samarium Sm-153 lexidronam
- samarium-153 lexidronam
- samarium-153-EDTMP
- Sm-EDTMP
◉ Summary of Use during Lactation
Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered.
Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
- Drugs and Lactation Database (LactMed)Samarium Sm 153 Lexidronam Pentasodiumhttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1130/
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeQuadramet (EMEA/H/C/000150)https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet
- EU Clinical Trials Register
- PubChem
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlsamarium Sm-153 lexidronamhttps://www.ncbi.nlm.nih.gov/mesh/67061972Analgesics, Non-Narcotichttps://www.ncbi.nlm.nih.gov/mesh/68018712